ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för bosutinib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

27 träffar

Bibliografisk träff 2012-09-04

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.

Cortes JE, Kim DW, Kantarjian HM, Brümmendorf TH, Dyagil I, Griskevicius L, Malhotra H, Powell C, Gogat K, Countouriotis AM, Gambacorti-Passerini C.

J Clin Oncol · clinical trial, phase iii; comparative study; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1200/jco.2011.38.7522

Bibliografisk träff 2012-08-09

Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.

Abbas R, Leister C, El Gaaloul M, Chalon S, Sonnichsen D.

Clin Ther · comparative study; research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1016/j.clinthera.2012.07.006

Bibliografisk träff 2012-08-03

Treatments for chronic myeloid leukemia: a qualitative systematic review.

Ferdinand R, Mitchell SA, Batson S, Tumur I.

J Blood Med · review-article; journal article · DOI 10.2147/jbm.s33380

Bibliografisk träff 2012-05-16

Denosumab--a powerful RANKL inhibitor to stop lytic metastases and other bone loss actions by osteoclasts.

Kopper L.

Pathol Oncol Res · review; journal article · DOI 10.1007/s12253-012-9538-4

Bibliografisk träff 2012-04-06

Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain.

Levinson NM, Boxer SG.

PLoS One · research-article; journal article; research support, n.i.h., extramural · DOI 10.1371/journal.pone.0029828

Bibliografisk träff 2012-03-03

HPLC-DAD protein kinase inhibitor analysis in human serum.

Dziadosz M, Lessig R, Bartels H.

J Chromatogr B Analyt Technol Biomed Life Sci · journal article · DOI 10.1016/j.jchromb.2012.02.037

Bibliografisk träff 2012-03-01

Bosutinib for the treatment of chronic myeloid leukemia in chronic phase.

Quintás-Cardama A, Kantarjian H, Cortes J.

Drugs Today (Barc) · review; journal article · DOI 10.1358/dot.2012.48.3.1750274

Bibliografisk träff 2012-02-27

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, Zaritskey A, Countouriotis A, Besson N, Leip E, Kelly V, Brümmendorf TH.

Blood · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1182/blood-2011-11-390120

Bibliografisk träff 2012-02-01

[Characteristics and outcome of chromosomal abnormalities in Ph negative cells of chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors].

Mu QT, Chen ZM, Lou JY, Cheng YZ, Wang YG, Jin J.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi · journal article; english abstract · DOI 10.3760/cma.j.issn.1003-9406.2012.01.016

Bibliografisk träff 2012-01-23

SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer.

Kim WG, Guigon CJ, Fozzatti L, Park JW, Lu C, Willingham MC, Cheng SY.

Clin Cancer Res · research support, n.i.h., intramural; research-article; journal article · DOI 10.1158/1078-0432.ccr-11-2892

Bibliografisk träff 2012-01-01

Src kinase inhibitors: promising cancer therapeutics?

Creedon H, Brunton VG.

Crit Rev Oncog · review; journal article · DOI 10.1615/critrevoncog.v17.i2.20

Bibliografisk träff 2012-01-01

A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia.

Robak P, Robak T.

Curr Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.2174/092986712803833371

Bibliografisk träff 2011-12-16

Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.

Daud AI, Krishnamurthi SS, Saleh MN, Gitlitz BJ, Borad MJ, Gold PJ, Chiorean EG, Springett GM, Abbas R, Agarwal S, Bardy-Bouxin N, Hsyu PH, Leip E, Turnbull K, Zacharchuk C, Messersmith WA.

Clin Cancer Res · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-11-2378

Bibliografisk träff 2011-12-14

A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects.

Abbas R, Hug BA, Leister C, Sonnichsen D.

Int J Cancer · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1002/ijc.27348

Bibliografisk träff 2011-11-03

Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation.

Uz B, Bektas O, Eliacık E, Goker H, Erbilgin Y, Sayitoglu M, Sayinalp N, Aksu S, Buyukasik Y, Ozcebe O, Haznedaroglu IC.

Case Rep Hematol · case reports; case-report · DOI 10.1155/2011/263725

Bibliografisk träff 2011-10-28

Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia.

Trask PC, Cella D, Besson N, Kelly V, Masszi T, Masszi T, Kim DW.

Leuk Res · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1016/j.leukres.2011.10.011

Bibliografisk träff 2011-10-28

Identification of a Src tyrosine kinase/SIAH2 E3 ubiquitin ligase pathway that regulates C/EBPδ expression and contributes to transformation of breast tumor cells.

Sarkar TR, Sharan S, Wang J, Pawar SA, Cantwell CA, Johnson PF, Morrison DK, Wang JM, Sterneck E.

Mol Cell Biol · research support, n.i.h., intramural; research-article; journal article; research support, n.i.h., extramural · DOI 10.1128/mcb.05790-11

Bibliografisk träff 2011-10-26

Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport.

Braun D, Kim TD, le Coutre P, Köhrle J, Hershman JM, Schweizer U.

J Clin Endocrinol Metab · research support, non-u.s. gov't; journal article · DOI 10.1210/jc.2011-1837

Bibliografisk träff 2011-08-24

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.

Cortes JE, Kantarjian HM, Brümmendorf TH, Kim DW, Turkina AG, Shen ZX, Pasquini R, Khoury HJ, Arkin S, Volkert A, Besson N, Abbas R, Wang J, Leip E, Gambacorti-Passerini C.

Blood · clinical trial, phase ii; research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1182/blood-2011-05-355594

Bibliografisk träff 2011-06-23

Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy.

Campone M, Bondarenko I, Brincat S, Hotko Y, Munster PN, Chmielowska E, Fumoleau P, Ward R, Bardy-Bouxin N, Leip E, Turnbull K, Zacharchuk C, Epstein RJ.

Ann Oncol · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1093/annonc/mdr261

Bibliografisk träff 2011-06-21

A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.

Abbas R, Hug BA, Leister C, Gaaloul ME, Chalon S, Sonnichsen D.

Cancer Chemother Pharmacol · research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1007/s00280-011-1688-7

Bibliografisk träff 2011-06-16

KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.

Gleixner KV, Mayerhofer M, Cerny-Reiterer S, Hörmann G, Rix U, Bennett KL, Hadzijusufovic E, Meyer RA, Pickl WF, Gotlib J, Horny HP, Reiter A, Mitterbauer-Hohendanner G, Superti-Furga G, Valent P.

Blood · research support, non-u.s. gov't; journal article · DOI 10.1182/blood-2010-06-289959

Bibliografisk träff 2011-05-05

Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors.

Tibullo D, Barbagallo I, Giallongo C, La Cava P, Branca A, Conticello C, Stagno F, Chiarenza A, Palumbo GA, Di Raimondo F.

Hematol Oncol · research support, non-u.s. gov't; journal article · DOI 10.1002/hon.988

Bibliografisk träff 2010-12-08

Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects.

Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D.

J Clin Pharmacol · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1177/0091270010387427

Bibliografisk träff 2009-06-09

Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts.

Messersmith WA, Rajeshkumar NV, Tan AC, Wang XF, Diesl V, Choe SE, Follettie M, Coughlin C, Boschelli F, Garcia-Garcia E, Lopez-Rios F, Jimeno A, Hidalgo M.

Mol Cancer Ther · research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1158/1535-7163.mct-09-0075

Bibliografisk träff 2008-11-27

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.

Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, Müller A, Baumgartner C, Valent P, Augustin M, Till JH, Superti-Furga G.

Leukemia · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1038/leu.2008.334

Bibliografisk träff 2008-05-01

SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.

Vultur A, Buettner R, Kowolik C, Liang W, Smith D, Boschelli F, Jove R.

Mol Cancer Ther · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1535-7163.mct-08-0126